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Alzheimer diseaseIn previous studies we have demonstrated that prion protein (PrP) interacts with tubulin and disrupts
microtubular cytoskeleton by inducing tubulin oligomerization. These observations may explain the
molecular mechanism of toxicity of cytoplasmic PrP in transmissible spongiform encephalopathies (TSEs).
Here, we check whether microtubule associated proteins (MAPs) that regulate microtubule stability,
inﬂuence the PrP-induced oligomerization of tubulin. We show that tubulin preparations depleted of MAPs
are more prone to oligomerization by PrP than those containing traces of MAPs. Tau protein, a major neuronal
member of theMAPs family, reduces the effect of PrP. Importantly, phosphorylation of Tau abolishes its ability
to affect the PrP-induced oligomerization of tubulin. We propose that the binding of Tau stabilizes tubulin in a
conformation less susceptible to oligomerization by PrP. Since elevated phosphorylation of Tau leading to a
loss of its function is observed in Alzheimer disease and related tauopathies, our results point at a possible
molecular link between these neurodegenerative disorders and TSEs.assie brilliant blue; CtmPrP,
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Cellular prion protein (PrPC), particularly in a misfolded form
(PrPSc), is widely considered a key player in the pathogenesis of
neurodegenerative diseases called TSEs [1,2]. Nonetheless, the
molecular mechanisms of the pathogenic misfolding as well as the
PrP-mediated neurodegeneration remain unresolved. PrPC is a mostly
extracellular glycoprotein anchored in the plasma membrane [3]. In
pathology, however, its intracellular concentration signiﬁcantly raises.
PrP point mutations linked to some TSEs increase the fraction of a
transmembrane form of PrP (CtmPrP) with the C-terminal domain
localized in endoplasmic reticulum (ER) lumen and the N-terminal
domain exposed to the cytosol [4,5]. C-terminally truncated stop
mutants of PrP are detected in the cytosol and nucleus [6,7].
Furthermore, accumulation of cytosolic PrP (cytoPrP) may result from
the ER stress common in TSEs, affected translocation of nascent PrP,
and direct inhibition of the proteasome by PrPSc [8–10]. Importantly,
intracellular PrP has been demonstrated to be neurotoxic [4,11,12]. It ispostulated that mislocalized PrP may exert toxic effects through
interactions with intracellular proteins leading to loss or modiﬁcation
of their physiological functions [10,13]. In line with this hypothesis
co-aggregation of several cytosolic proteins with cytoPrP has been
reported. For example, cytoPrP co-aggregated the anti-apoptotic
protein Bcl-2 and the ubiquitin ligase mahogunin [14,15]. Moreover,
we have demonstrated that PrP binds to tubulin and disrupts
microtubular cytoskeleton by inducing tubulin oligomerization and
formation of aggregates [16–18]. Subsequently, it was also found that
PrPSc co-immunoprecipitated with tubulin in brain homogenates of
TSE-infected animals [19]. Interestingly, loss of dendritic microtubules
has been observed in ultrastructural studies of TSE brain sections [20].
Tubulin is the major building block of microtubules – dynamic
cytoskeletal structures involved in crucial cellular functions [21]. The
assembly and stability of microtubules are regulated by microtubule
associated proteins (MAPs) [22]. One of the major neuronal MAPs is
Tau protein whose dysfunction leads to neurodegeneration observed
in Alzheimer disease (AD) and other tauopathies [23]. Phosphoryla-
tion of Tau reduces its binding to tubulin and thereby regulates
microtubule dynamics. Hyperphosphorylation of Tau, a hallmark of
AD, leads to its aggregation into paired helical ﬁlaments, disassembly
of microtubular cytoskeleton, and neurodegeneration. Interestingly,
hyperphosphorylation of Tau has also been reported in human TSEs
cases [24–27]. This may result from induction of Tau hyperpho-
sphorylation by misfolded PrP [28,29] indicating a molecular link
between these protein misfolding diseases (PMDs). Furthermore, a
direct interaction between PrP and Tau has been demonstrated [30].
Here, we checked whether MAPs/Tau protein may inﬂuence the
PrP-induced oligomerization of tubulin. We have also veriﬁed an
intriguing scenario where phosphorylation of Tau enhances the
1846 K.M. Osiecka et al. / Biochimica et Biophysica Acta 1813 (2011) 1845–1853deleterious effect of PrP exerted at the level of the microtubular
cytoskeleton.
2. Materials and methods
2.1. Protein puriﬁcation
Human prion protein (residues 23–231)was expressed in E. coli and
puriﬁed asdescribedpreviously [31,32]. As itwasdemonstratedbyZahn
and colleagues [32], the applied puriﬁcation procedure gives natively
folded PrP. To ensure that PrPwasnot aggregated the preparationswere
ultracentrifuged (30 min at 200,000 g, 30 °C) before each experiment.
Tubulin containing traces of MAPs (crude tubulin)was puriﬁed from
porcine brain by two cycles of polymerization/depolymerization
according to the modiﬁed method of Mandelkow and colleagues [33],
described in details in [16]. The last step of microtubule depolymeriza-
tion was performed either for 2 or 12 h. Tubulin preparations were
stored at−70 °C in PM buffer composed of 2 mM EGTA, 0.1 mM EDTA,
1 mMATP, 2 mMDTTand100 mMPIPESpH6.9. Just before experiments
the preparations were thawed and centrifuged for 20 min at 22,000 g,
4 °C. Obtained supernatants were used as crude tubulin.
Crude tubulin was depleted of MAPs by the modiﬁed method of
Castoldi and Popov [34]. Tubulin supernatant, obtained as described
above, was incubated with equal volume of 20% DMSO, 2 mM MgCl2,
2 mMGTP and 1 M PIPES pH 6.9 for 1 h at 37 °C. Themixture was then
layered (1:2, v/v) over a cushion composed of 60% glycerol, 1 mM
EGTA, 1 mM MgCl2, 80 mM PIPES pH 6.9 (warmed to 37 °C), and
centrifuged for 1 h at 200,000 g, 37 °C. The obtained pellet of pure
microtubules was brieﬂy rinsed and homogenized in PM buffer on ice.
The resuspended pellet was used at the day of preparation as pure
tubulin. The supernatant, was dialyzed against 0.3 M KCl, 1 mM EDTA,
0.1 mM DTT, 0.5 mM PMSF and 10 mM MOPS pH 6.8 and subse-
quently used for preparation of MAPs fraction. MAPs were separated
from remnants of tubulin on DEAE Sephacel according to Murphy and
colleagues [35]. The fractions containing MAPs were concentrated on
Centriprep (Millipore, Billerica, MA, USA) and dialyzed against 50 mM
NaCl, 1 mM EDTA, 0.1 mM DTT, 0.5 mM PMSF and 10 mM MOPS pH
6.8, and stored at −70 °C.
Brain Tau was puriﬁed directly from crude tubulin or from
supernatants obtained upon centrifugation of crude tubulin over the
glycerol cushion. Tau preparations of different electrophoretic
mobility were obtained from tubulin depolymerized by incubation
for different lengths of time (see above). Generally, preparations of
higher electrophoretic mobility (H) were obtained from tubulin
depolymerized for 2 h whereas those of lower mobility (L) from
tubulin depolymerized for 12 h. Initial preparations were dialyzed
against 0.75 M NaCl, 1 mM MgCl2, 2 mM EGTA, 2% β-ME, 0.5 mM
PMSF and 20 mM MES pH 6.8. Then, according to the method of
Fellous and colleagues [36], the preparations were boiled for 5 min in
a water bath and after cooling centrifuged for 30 min at 29,000 g, 4 °C.
Obtained supernatants were treated with 2.5% perchloric acid as
described by Lindwall and Cole [37], and immediately centrifuged for
15 min at 14,000 g, 25 °C. Subsequently, Tau was salted out from
supernatants by ammonium sulfate at 50% saturation. The preparation
was centrifuged for 30 min at 42,000 g, 4 °C. Tau pellet was
resuspended, dialyzed against 50 mM NaCl, 0.5 mM EGTA, 1 mM
DTT, 0.5 mM PMSF and 50 mM MES pH 6.8, and stored at −70 °C.
Recombinant Tau (rTau, human isoform 2N4R) was purchased
from Sigma (St. Louis, MO, USA). If not indicated otherwise, rTau at
28 μg/ml (0.6 μM) was used.
2.2. Phosphorylation of Tau
rTau at 0.85 mg/ml was incubated with catalytic subunit of PKA
(Sigma) added at the proportion of 60 μg/mg of Tau for 2 h at 37 °C in
28 mM NaCl, 10 mM MgCl2, 0.28 mM EGTA, 1.2 mM DTT and 28 mMMES pH 6.8. The phosphorylation was initiated by addition of 1 mM
ATP. After 2 h, the buffer was supplemented with 0.01% Triton X-100
and the concentrations of NaCl, DTT and ATP were increased to
76 mM, 1.8 mM and 2 mM, respectively, whereas pHwas increased to
7.4 with 16 mM Tris–HCl. The mixture was then incubated with
GSK3β (GenScript, Piscataway, NJ, USA) at the proportion of 26 μg/mg
of Tau for 3 h at 37 °C. In some experiments Tau was phosphorylated
solely by PKA for 5 h. Solubility of phosphorylated Tau was conﬁrmed
in sedimentation experiments by centrifugation for 10 min at
200,000 g, 4 °C. The extent of phosphorylation was assessed by shift
in electrophoretical mobility upon SDS-PAGE.
2.3. Dephosphorylation of Tau
Brain Tau at 0.4 mg/ml was incubated with phosphatase PP2A
(Millipore) at the proportion of 17 μg/mg of Tau for 2 h at 30 °C in
240 mM NaCl, 0.4 mM MgCl2, 0.04 mM MnCl2, 0.7 mM EGTA, 25 mM
β-ME, 1 mMDTT, 0.3 mM PMSF and 30 mMMES pH 6.8. The extent of
dephosphorylation was assessed by SDS-PAGE and Western blotting.
2.4. Light scattering
Oligomerization of tubulin was assessed by turbidity measure-
ments as previously described [17] at conditions not allowing
microtubule formation. Tubulin at 0.2 mg/ml (4 μM, assuming
molecular weight≈50,000) was incubated at 25 °C in a buffer
containing 10% (w/v) glycerol, 1 mM GTP, 16 mM MgCl2 and 10 mM
sodium phosphate buffer pH 7.0. In some experiments the buffer was
supplemented with 50 μMCaCl2. Monitoring of turbidity was initiated
immediately after addition of PrP (ﬁnal concentration of 10 or 15 μg/ml,
corresponding to 0.4 or 0.6 μM) to the cuvette. All measurements
were performed against tubulin or tubulin with MAPs/Tau as a
reference.
2.5. Cross-linking experiments
Covalent cross-linking was performed at the same conditions and
protein concentrations as the turbidity measurements. The reaction
was initiated by addition of 1 mM SNHS and 1 mM EDC. After 1 h of
incubation at 25 °C, cross-linking was stopped with 50 mM Tris. The
cross-linking products were analyzed by SDS-PAGE and Western
blotting.
2.6. Transmission electron microscopy
The samples analyzed by light scattering were also subjected to
electronmicroscopic studies. After 20 min of incubation at 25 °C, 10-μl
samples were placed on copper grids (400mesh, Sigma) covered with
collodion (SPI Supplies, West Chester, PA, USA) and carbon. Negative
staining was performed with 2% (w/v) uranyl acetate (SPI Supplies)
for 25 s. The grids were examined in a JEM 1400 electron microscope
(JEOL Co., Japan) equipped with a digital camera (CCD MORADA, SiS-
Olympus, Germany).
2.7. Electrophoretic separations
SDS-PAGE was performed on 10% separating gels according to
Laemmli [38]. To improve separation of Tau preparations, the
electrophoresis was continued until the 50 kDa marker reached
the edge of the gel. The gels were stained with Coomassie brilliant
blue R-250.
2.8. Western blotting
After SDS-PAGE proteinswere electrotransferred onto nitrocellulose
membrane (Amersham Biosciences, Piscataway, NJ, USA) in a standard
Fig. 1. MAPs reduce PrP-induced turbidity of tubulin. In A tubulin (0.2 mg/ml)
containing endogenous MAPs (■) or tubulin depleted of MAPs (□) was incubated with
PrP (10 μg/ml). Inset shows Tau detected by Western blotting in preparation of tubulin
containing endogenous MAPs (1) but not in pure tubulin preparation (2). In B tubulin
(0.2 mg/ml) depleted of MAPs was incubated with PrP (10 μg/ml) in the presence of
isolated MAPs fraction at 0 (□), 40 ( ) or 80 μg/ml (■). Inset shows MAPs fraction on
Coomassie-stained gel (CBB) and Western blot analyzed with anti-Tau antibody (WB).
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primary antibody mAb 6H4 (Prionics AG, Schlieren, Switzerland)
diluted at 1:5,000. Tau was detected by primary antibody mAb T8201
(Sigma) diluted at 1:1,000. Then, goat secondary antibody AP308P anti-
mouse IgG (Millipore) conjugated with horseradish peroxidase (HRP)
diluted at 1:5,000 was used. β-actin was detected by antibody mAb
A3854 (Sigma) conjugated with HRP, diluted at 1:100,000. Antigen
detections were carried out by incubation of the blots with a
chemiluminescent HRP substrate (Millipore) followed by exposition
against X-ray ﬁlms (Kodak, Rochester, NY, USA).
2.9. Peptide synthesis
PeptideMANLGYWLLALFVTMWTDVGLCKKRPKPGG-NH2 (pep1-30)
corresponding tomouse PrP sequence1–30 (residues 23–30 identical to
human PrP), was synthesized commercially (EZBiolab, Westﬁeld, IN,
USA). The peptide was of 96% purity as determined by HPLC and mass
spectrometry analyses. Pep1-30 was dissolved in deionized water.
2.10. Cell culture
Human epithelial cells (HEp-2) were purchased from American
Type Culture Collection (Rockville, MD, USA) and were cultured in
modiﬁed Eagle's medium containing 25 mM glucose, 2 mM L-
glutamine, 10% fetal bovine serum, 100 units/ml penicillin and,
100 μg/ml streptomycin. Cells were grown in a humidiﬁed incubator
with 5% CO2 at 37 °C. The culture medium was changed every 2–
3 days and cells were passaged when conﬂuent.
Plasmid pET29b encoding human Tau (2N4R) described by
Hedgepeth and colleagues [39] was purchased from Addgene
(Cambridge, MA, USA). Tau coding sequence was ampliﬁed from
plasmid Tau/pET29b with primers tau5Not (5′-TAGCGGCCG-
CATGGCTGAGCCCCGCCAG-3′) and tauSTOP3Bgl2 (5′-TAAGATCTAT-
CACAAACCCTGCTTGGCCAGG-3′). PCR product was digested with NotI
and BglII and cloned into p3xFLAG-CMV-14 vector (Sigma) digested
with the same enzymes. Correctness of the ﬁnal construct was
conﬁrmed by dideoxy sequencing. The cells were transfected either
with Tau/pCMV14 or empty plasmid using Lipofectamine 2000
(Invitrogen) according to the manufacturer's protocol.
Transfected HEp-2 cells seeded the day before experiment onto
coverslips were treated with 0.5 or 1 μM (ﬁnal concentration) pep1-30
in the culture medium. After 1 h the cells were ﬁxed for 20 minwith 3%
paraformaldehyde in PBS.
2.11. Immunoﬂuorescence microscopy
Fixed HEp-2 cells were washed with PBS and treated with 50 mM
NH4Cl in PBS for 15 min, washed with PBS and permeabilized with
0.05% Triton X-100 in PBS for 4 min at 4 °C. After washingwith PBS the
cells were incubated with 2% horse serum in PBS for 1 h at 25 °C and
subsequently incubated with antibodies to β-tubulin (T0198, Sigma)
diluted at 1:500 in 2% horse serum (in PBS) for 16 h at 4 °C. The cells
were then washed with PBS and incubated with antibodies to mouse
IgG conjugated with ALEXA 546 (Jackson ImmunoResearch Labora-
tories, West Grove, PA, USA) at 1:1000 for 1 h at room temperature,
washed with PBS and mounted on glass slides. The cells were
analyzed in confocal microscope Leica TCS SP5.
3. Results
Previously we described the effects of PrP on tubulin preparations
containing traces of endogenous MAPs (crude tubulin). Those studies
showed that PrP induced rapid oligomerization and aggregation of
tubulin [17,18]. Since MAPs regulate the stability of structures formed
by tubulin, here we checked the inﬂuence of these proteins on the PrP
effect on tubulin oligomerization. First we compared the effects of PrPon crude tubulin (containing traces of MAPs) and tubulin depleted of
MAPs (pure tubulin). Co-puriﬁed MAPs constituted ~10% of total
protein in crude tubulin preparations. We conducted these studies at
conditions not allowing microtubule formation (low tubulin concen-
tration) to avoid co-occurrence of tubulin oligomerization by PrP with
microtubule assembly by MAPs, both resulting in an increase in the
turbidity of tubulin samples. As previously reported [17] tubulin alone
gives no light scattering. Fig. 1A shows that the turbidity induced by
PrP in preparations of tubulin containing endogenous MAPs is much
weaker than that in preparations of pure tubulin. This suggests that
crude tubulin is less susceptible to PrP-induced oligomerization than
is pure tubulin. As expected, MAPs fraction isolated from preparations
of crude tubulin reduced the PrP-induced oligomerization of pure
tubulin (Fig. 1B). TheMAPs fraction added alone to tubulin induced no
light scattering (data not shown) indicating that in fact microtubules
were not formed at the conditions applied. Since Tau protein is one of
the major components of neuronal MAPs fraction we checked
whether it was also present in our preparations. As the Western
blot (inset in Fig. 1A) shows, crude tubulin contained Tau whereas
tubulin depleted of MAPs was free of this protein. Tau was also
present in the isolated MAPs fraction used in experiments demon-
strated in Fig. 1B (see the CBB-stained gel andWestern blot in Fig. 1B).
To check whether Tau is responsible for the effect described above
we puriﬁed it from brain tubulin preparations. Tau preparations of
different electrophoretic mobility were obtained (Western blot in
Fig. 2, compare lanes H and L), depending on the tubulin puriﬁcation
Fig. 3. Dephosphorylated brain Tau regains ability to reduce PrP-induced turbidity of
tubulin. Tubulin (0.2 mg/ml) was incubated with PrP (15 μg/ml) in the absence (□) or
presence (■) of Tau fraction of lower electrophoretic mobility (L, 56 μg/ml) subjected
to dephosphorylation with phosphatase PP2A. Compare with Fig. 2B obtained for L
fraction of Tau before dephosphorylation. Western blot shows untreated (−) and
dephosphorylated with PP2A (+) Tau.
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electrophoretic mobility (H) to pure tubulin resulted in the reduction
of PrP-induced oligomerization (Fig. 2A), whereas a Tau fraction of
lower electrophoretic mobility (L) had no effect on the oligomeriza-
tion (Fig. 2B). Either Tau preparation added alone did not inﬂuence
the light scattering by tubulin samples (data not shown). The
observed differences in the apparent molecular mass of Tau may
result from its varied level of phosphorylation, the major posttrans-
lational modiﬁcation of Tau affecting its interaction with tubulin.
Therefore we checked whether phosphorylation was in fact respon-
sible for the different features of our Tau preparations. We subjected
the Tau fraction of lower electrophoretic mobility (L), which was
ineffective in inhibition of the PrP-induced tubulin oligomerization
(Fig. 2B), to dephosphorylation by phosphatase PP2A. Treatment with
PP2A increased the electrophoretic mobility of Tau (Western blot
in Fig. 3, compare lanes marked “−” and “+”) accompanied by a
substantial restoration of the ability to decrease the PrP-induced
oligomerization of tubulin (Fig. 3). Subsequently, we showed that
recombinant human Tau (rTau) puriﬁed from E. coli inhibited the PrP-
induced tubulin oligomerization (Fig. 4A), indicating that this effect
requires no eukaryotic posttranslational modiﬁcations.
It is widely accepted that GSK3 is the main kinase responsible for
modiﬁcation of Tau at physiological as well as pathological conditionsFig. 2. Effect of Tau puriﬁed from brain on PrP-induced turbidity of tubulin. In A pure
tubulin (0.2 mg/ml) was incubated with PrP (15 μg/ml) in the presence of 0 (□), 28 ( )
or 56 μg/ml (■) of Tau fraction of high electrophoretic mobility (H). In B the incubation
was performed in the absence (□) or presence (■) of Tau fraction of lower
electrophoretic mobility (L, 56 μg/ml). Inset shows Western blot for Tau fractions of
higher (H) and lower electrophoretic mobility (L).(rev. in [23]). It has also been demonstrated that phosphorylation of
Tau by GSK3 is enhanced by prior phosphorylation by PKA [40].
Hence, to conﬁrm the role of phosphorylation, we subjected puriﬁed
recombinant Tau to sequential modiﬁcation by PKA and GSK3. As it is
shown in Fig. 4, unphosphorylated rTau reduces the PrP-induced
oligomerization (Fig. 4A) whereas the phosphorylated protein is
ineffective (Fig. 4B). As expected, phosphorylated rTau exhibited a
decreased electrophoretic mobility (gel in Fig. 4B, compare lanes 1
and 2). Similar effect of phosphorylation by PKA/GSK3 we have
observed for dephosphorylated brain Tau (see Supplementary data,
Fig. 1S). Interestingly, phosphorylation by PKA alone had no effect on
the ability of rTau to reduce the PrP-induced tubulin oligomerization
(Fig. 4C), although Tau was readily modiﬁed by this kinase (gel in
Fig. 4C, compare lanes 1 and 2). Neither phosphorylated nor untreated
rTau added alone increased the light scattering by tubulin samples
(data not shown).
We then compared the ability of unmodiﬁed rTau and rTau
phosphorylated by PKA/GSK3 to bind to tubulin. As reported by
Sengupta and colleagues [41], the protein phosphorylated by both
kinases exhibited reduced afﬁnity to microtubules, whereas that
modiﬁed by PKA alone had an almost unchanged afﬁnity. Consistent-
ly, reduced binding to tubulin was also demonstrated for rTau
phosphorylated with PKA/GSK3 in our cross-linking experiments
performed at the conditions not allowing microtubule formation
(Fig. 5). These observations suggest that the phosphorylation may
lessen the inﬂuence of Tau on the PrP-induced oligomerization by
reducing the binding of Tau to tubulin.
To dissect the molecular mechanism of Tau action further we
examined the effects at the level of PrP interaction with tubulin. We
made use of the observation that PKA/GSK3-phosphorylated Tau lacks
the ability to affect the PrP-induced oligomerization of tubulin
(Fig. 4B). We compared the binding of PrP to tubulin in the absence
or presence of unphosphorylated rTau or rTau phosphorylated by
PKA/GSK3 under conditions of the light scattering experiments. As
demonstrated in Fig. 6, the yield of PrP-tubulin cross-linking is not
affected by Tau protein, independently of its phosphorylation status.
This suggests that Tau does not exert its effect by affecting the binding
of PrP to tubulin.
Since calcium ions compete with Tau for a binding site in the
C-terminal domain of tubulin [42], we checked whether this cation
could also abolish the Tau effect on the PrP-induced tubulin
oligomerization. As demonstrated in Fig. 7, Ca2+ does not affect the
PrP-induced oligomerization, implying that the binding sites on
Fig. 4. A. Recombinant Tau reduces PrP-induced turbidity of tubulin. Tubulin (0.2 mg/ml)
was incubated with PrP (15 μg/ml) in the absence (□) or presence of rTau at 7 ( ),
14 ( ) or 28 μg/ml (■). The tubulin/PrP/rTau molar ratios were 4:0.6:0.15 or 0.3 or 0.6,
respectively. Note barely detectable effect of rTau (during ﬁrst twomin of assay) even at
as low as 0.15:4 molar ratio to tubulin. B. Sequential phosphorylation of recombinant
Tau by PKA and GSK3 kinases abolishes its effect on PrP-induced turbidity of tubulin.
Tubulin (0.2 mg/ml) was incubated with PrP (15 μg/ml) in the absence (□) or presence
(■) of rTau (28 μg/ml) phosphorylated sequentially with PKA and GSK3. The tubulin/
PrP/rTau molar ratio was 4:0.6:0.6. Inset shows Coomassie-stained gel for
rTau untreated (1) and phosphorylated with PKA/GSK3 (2). C. Phosphorylation of
recombinant Tau by PKA alone has no effect on PrP-induced turbidity of tubulin. Tubulin
(0.2 mg/ml) was incubated with PrP (15 μg/ml) in the absence (□) or presence of
untreated rTau (28 μg/ml, ■) or rTau (28 μg/ml) phosphorylated with PKA ( ). The
tubulin/PrP/rTaumolar ratiowas 4:0.6:0.6. Coomassie-stained gel shows rTau untreated
(1) and phosphorylated with PKA alone (2).
Fig. 5. Phosphorylation of Tau reduces its binding to tubulin. Tubulin (0.2 mg/ml) was
cross-linked by EDC with untreated (1) or phosphorylated with PKA/GSK3 (2) rTau
(28 μg/ml). The tubulin/rTau molar ratio was 4:0.6. Western blot was analyzed with
anti-Tau antibody. Bands migrating above 120 kDa marker correspond to cross-linking
products of Tau with tubulin monomers (dissociated by SDS), tubulin heterodimers and
higher tubulin oligomers. Note reduced concentration of the cross-links with
phosphorylated tau.
Fig. 6. Tau does not reduce PrP binding to tubulin. In A PrP (15 μg/ml) was cross-linked
by EDC with tubulin (0.2 mg/ml) in the absence (1) or presence of untreated (2) or
dephosphorylated with PP2A (3) brain Tau (L, 56 μg/ml). In B PrP (15 μg/ml) was cross-
linked with tubulin (0.2 mg/ml) in the absence (1) or presence of untreated (2) or
phosphorylated with PKA/GSK3 (3) rTau (28 μg/ml). The tubulin/PrP/rTau molar ratio
was 4:0.6:0.6. Western blots were analyzed with anti-PrP antibody.
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PrP. Importantly, calcium signiﬁcantly reduced the Tau effect on the
PrP-induced oligomerization (Fig. 7). This suggests that Tau inﬂuencesthe PrP-induced oligomerization by interaction with tubulin in a
region different from the docking site for PrP.
To gain an insight into the effect of Tau on the structures formed by
tubulin, we performed electron microscopic analysis. In these studies
we compared the morphology of tubulin samples in the presence of
PrP alone or PrP together with rTau (Fig. 8). As formerly demonstrated
[17,18], PrP induced tubulin oligomerization and assembly of large
aggregates of tubulin oligomers. Also numerous ring-shaped struc-
tures and their fragments, both characteristic for tubulin incubated at
conditions not allowing microtubule formation and at high concen-
trations of magnesium [43,44], were observed in these samples
(Fig. 8). As expected, oligomerization of tubulin and formation of
aggregates was inhibited in samples containing Tau (Fig. 8). This was
accompanied by an increase in the number of the ring-shaped
structures. The number of small globular oligomers found in tubulin
incubated alone was reduced after addition of Tau. These oligomers
were almost absent in the presence of both Tau and PrP. Notably, we
found no ring-shaped structures in tubulin incubated alone, whereas
they were present in samples containing Tau or PrP and were most
abundant in the presence of Tau togetherwith PrP. These observations
Fig. 7. Calcium reduces effect of Tau on PrP-induced turbidity of tubulin. Tubulin
(0.2 mg/ml) was incubated with PrP (15 μg/ml) in the absence (□) or presence (■) of
rTau (28 μg/ml). After addition of calcium, tubulin was similarly incubated with PrP
(15 μg/ml) in the absence (○) or presence (●) of rTau (28 μg/ml). The tubulin/PrP/rTau
molar ratio was 4:0.6:0.6.
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oligomers (or other amorphous structures) which are less susceptible
to PrP-mediated oligomerization and aggregation.
To check whether Tau is capable of protecting the microtubular
cytoskeleton against PrP-induced disassembly, we subjected human
epithelial cells (HEp-2) transfected either with empty or Tau-Fig. 8. Tau inhibits formation of PrP-induced tubulin oligomers/aggregates. Electron micr
incubated with rTau (28 μg/ml) or tubulin incubated with both rTau (28 μg/ml) and PrP (1
Fig. 9. Tau protects microtubular cytoskeleton of cultured cells from disassembly by PrP pep
(lane 2) but not these transfected with empty plasmid (lane 1) express Tau protein. β-acti
untreated HEp-2 cells (A, B) as well as treated with 0.5 (C, D) or 1 μM pep1-30 (E, F) was pe
themicrotubular cytoskeleton of peptide-treated cells transfected with empty vector (pCMV
cell rounding (C, E). At the same time, cells transfected with plasmid encoding Tau (Tau/pCM
in the entire cytoplasm in the presence of 0.5 μM pep1-30 (D). Tau-expressing cells seem toencoding plasmid to treatment with PrP peptide 1–30 (pep1-30).
This peptide encompasses themajor tubulin binding site (PrP residues
23–30) responsible for tubulin oligomerization and inhibition of
microtubule assembly [18]. As it was demonstrated previously, pep1-
30 of known ability to penetrate into cytoplasm of cultured cells [45],
induced disruption of the microtubular cytoskeleton of HEp-2 cells
[18]. Also in this study, already 0.5 μM pep1-30 caused disintegration
of the microtubular cytoskeleton accompanied by rounding of the
cells lacking Tau protein (Fig. 9C, E). At the same time, the cells
transfected with plasmid encoding Tau were apparently insusceptible
to the peptide applied at 0.5 μM concentration (Fig. 9D) and much
more resistant to 1 μM peptide than the cells transfected with empty
plasmid (Fig. 9F).
4. Disussion
In this study we have found that Tau protein may substantially
decrease the PrP-induced oligomerization of tubulin. As we have
demonstrated previously this oligomerization leads to inhibition of
microtubule formation which may have adverse consequences to the
cell [17]. Employing a membrane-penetrating peptide we have shown
that PrP fragment 1–30 encompassing the major tubulin binding site
(PrP residues 23–30) disrupts microtubular cytoskeleton of cultured
cells [18]. That observation was further conﬁrmed in cells transfected
with a plasmid encoding cytoPrP [46]. Herein, we have found that Tau
protects cultured cells from deleterious effect of PrP peptide 1–30. In
light of our present results one can assume that Tau is a negativeoscopy of tubulin (0.2 mg/ml) alone, tubulin incubated with PrP (15 μg/ml), tubulin
5 μg/ml). The tubulin/PrP/rTau molar ratio was 4:0.6:0.6.
tide 1–30. Western blot shows that HEp-2 cells transfected with Tau-encoding plasmid
n is shown as a loading control (lanes 1′ and 2′). Confocal ﬂuorescence microscopy of
rformed using antibodies to β-tubulin to visualize microtubular cytoskeleton. Note that
14) is disassembled and tubulin is congregated around the nuclei that is accompanied by
V14) exhibited normal morphology with tubulin forming a network of linear structures
be more resistant than the control cells also to 1 μM peptide (F). Scale bar is 5 microns.
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Furthermore, we have found that phosphorylation of Tau that, at an
elevated level, is a hallmark of AD, may indirectly enhance deleterious
effect of PrP on tubulin function.
What is the mechanism of Tau action? The above-described
inhibition of the PrP-induced tubulin oligomerization could in
principle result from: (i) competition between Tau and PrP for a
binding site on tubulin, (ii) interaction between Tau and PrP or (iii)
Tau-mediated stabilization of a tubulin structure less susceptible to
the oligomerization. Our observations imply that the Tau effect is
mediated through its interaction with tubulin, but is not a result of
competition between Tau and PrP for a binding site on tubulin. We
have found that neither unphosphorylated nor PKA/GSK-modiﬁed
Tau affects PrP-tubulin cross-linking. On the other hand, phosphor-
ylation of Tau by PKA/GSK reduces its binding to tubulin [40] as well
as its ability to prevent the PrP-induced oligomerization. Accordingly,
phosphorylation by PKA alone, which does not reduce Tau binding to
tubulin [41], also does not inﬂuence the Tau effect. Furthermore, in
our experiments, calcium reduced the Tau effect on the PrP-induced
oligomerization. This may be explained by the observation that
calcium competes with Tau for binding to the C-terminal domain of
tubulin [42]. Conversely, calcium did not affect the PrP-induced
oligomerization of tubulin, indicating that the binding sites for this
cation and PrP do not overlap. In fact, subtilisin-treated tubulin lacks
high afﬁnity calcium binding sites [47] whereas its ability to bind PrP
is not affected [18]. Altogether, the Tau effect on the PrP-inducedFig. 10. Proposed molecular cross-talk between hyper-phosphorylation of Tau and toxicity o
leads to dissociation of Tau from tubulin and disassembly of microtubules. Tubulin deplete
concentration is also elevated in TSEs. Tubulin co-aggregated with PrP is unable to form moligomerization is lessened when the binding of Tau to tubulin is
reduced either by phosphorylation or by calcium ions.
We found that even traces of MAPs present in preparations of
crude tubulin are capable of signiﬁcantly reducing the PrP effect. This
is consistent with the observation that traces of MAPs stabilize
microtubules efﬁciently [48]. This also suggests that MAPs/Tau exert
their effect through stabilization of particular structures of tubulin,
e.g. ring-shaped oligomers rather than through hindering the PrP
binding to tubulin. SinceMAPs are only present at a low concentration
in crude tubulin preparations, it is quite unlikely that they act through
sequestration of PrP.
We suppose that all MAPswhich are able to promote assembly and
stabilize microtubules can also make tubulin less susceptible to
oligomerization by PrP. Our preliminary studies indicate that also
MAP2 is able to inhibit PrP-induced oligomerization of tubulin
(unpublished observations). However, in this paper we focused on
Tau since hyperphosphorylation of this MAP, leading to loss of its
microtubule-stabilizing function, has been reported extensively in
prion diseases. Furthermore, hyperphosphorylated Tau sequesters not
only normal Tau but also other MAPs like MAP1 and MAP2 (rev. in
[23]). Therefore, Tau seems to be the key MAP in the neurodegenera-
tion processes related tomicrotubule disruption. Since Tau is localized
mainly in axons whereas MAP2 in dendrites, the effects of cytosolic
PrP on microtubular cytoskeleton could be controlled in both types of
neurites. Phosphorylation of MAPs is a common mechanism regulat-
ing their interactionwith tubulin hence it is reasonable to assume thatf cytosolic PrP. In TSEs misfolded PrP induces phosphorylation of Tau. This modiﬁcation
d of Tau becomes more susceptible to oligomerization/aggregation by cytoPrP whose
icrotubules.
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oligomerization.
In the light of our results, of particular relevance are observations
suggesting that PrPmay trigger phosphorylation of Tau. Accumulation
of hyperphosphorylated Tau in brains of TSE patients is amply
documented [24–27]. Deposits of hyperphosphorylated Tau, indistin-
guishable from those observed in AD, are frequently found in vicinity
of PrP plaques. Plaques with cores composed of PrP aggregates,
surrounded by Tau deposits, have been reported [49,50]. Hyperpho-
sphorylation of Tau has also been observed in animals experimentally
infected with TSE [51,52]. This co-occurrence of the hallmarks of TSE
and AD may have important pathological implications. The spatial
proximity of PrP and Tau aggregates suggests that they inﬂuence each
other's formation and/or cytotoxic effects. In fact, it has been
demonstrated that cells treated with amyloid composed of PrP
fragment 106–126 exhibit increased activity of GSK3 and cdk5
accompanied by hyperphosphorylation of Tau [28,29]. Another
molecular link between TSEs and AD has been provided by the
observation of PrP deposits in brains of patients with a familial form of
AD [53]. Recently, induction of Aβ peptide aggregation –which is also
a hallmark of AD – by PrPSc as well as aggregation of PrP by amyloid of
Aβ has been demonstrated [54]. These observations indicate that
pathology related to misfolded PrP may occur in AD. Hence, it is even
considered that common therapies could be applied for these PMDs
[54].
As illustrated schematically in Fig. 10, we postulate that Tau
phosphorylation may be an important factor enhancing neurotoxicity
of cytoPrP. It has been reported that in TSE misfolded PrP (i) induces
elevated phosphorylation of Tau [28,29] and (ii) directly inhibits
proteasome activity, thus facilitating accumulation of cytoPrP [9].
Both processes may lead to the disassembly of microtubular
cytoskeleton, the ﬁrst through a loss of microtubule stabilization by
phospho-Tau and increased susceptibility of Tau-depleted tubulin to
the PrP-induced oligomerization/aggregation, and the second — by
allowing cytosolic interaction of PrP with tubulin. It is plausible that
even at low concentrations of cytoPrP, a synergistic effect of Tau
hyperphosphorylation may evoke substantial toxicity at the level of
microtubular cytoskeleton of neurons. Taken together, our studies
point to a novel link between pathogeneses related to Tau and PrP.
Supplementarymaterials related to this article can be found online
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